| Item | Details |  
| ------------- | ------------- |  
| Deal structure   | Business Transfer Agreement (going concern), carved-out non oncology Rx formulations portfolio  | 
| Brands / SKUs | 23 brands, 67 SKUs  |  
| Therapeutic focus | Anti-infectives + pain management (plus smaller gastro + vitamins)  | 
| People | ~470 field staff (majority medical reps + area managers) | 
| Distribution  | 1,600+ stockists + established channel relationships  | 
| FY2024–25 (FY25) Net Sales  | ₹118.5 crore  | 
| FY25 EBITDA | ₹29.0 crore  | 
| Pipeline | 9 products (launch-ready mix, not all “new molecules”) | 
